Skin Analytics

📍 👋 We're at Holyrood’s Digital Health and Care Scotland 2025 - come and say hi! Rachael Dovey and Dr Dilraj K. just hosted a masterclass, demonstrating how implementing DERM can help address Scotland's dermatology challenges by: - increasing specialist level assessment in the community - promoting care closer to home - speeding up patient access to skin cancer diagnosis Holyrood Connect #DigiHealthCare25 #Scotland #AI Emma Etheredge Ian Gibbons Lyndsey Reeves

No more waiting. AI for skin cancer detection has arrived in Scotland. 📍 🚀 Rachael Dovey and Dr Dilraj K. will be hosting a masterclass session at Holyrood’s Digital Health and Care Scotland 2025 this week to demonstrate how DERM can transform dermatology services in Scotland. More here: https://lnkd.in/eZsQNVm7 Holyrood Connect #DigiHealthCare25 #Scotland

This week, our Rosie Stewart and Yasmine M. attended the Vitality Supplier Awards as a nominee for the Supplier of the Year award! 🪩🥳 This year marks 10 years of partnership between Vitality and Skin Analytics, so it was a privilege to be nominated for this award. This award recognises a supplier that provides unparalleled levels of service and who consistently puts Vitality at the forefront of their business whilst developing a true partnership between the two organisations. A huge congratulations to Qualitest who won on the evening! It’s great to be named amongst others championing innovative technologies. Vitality has partnered with Skin Analytics since 2015 to help thousands of members access fast dermatology skin cancer assessments, improving early detection and delivering better health outcomes. We are very much looking forward to another great year working together and continuing to innovate.

✅ When DERM identifies that a patient does not have a melanoma, DERM has been correct 99.9% of the time. Performing to this level enables NHS dermatology teams to safely and confidently discharge patients with benign skin lesions, reserving capacity for patients in greatest need. 📅 Learn how Chelsea and Westminster Hospital NHS Foundation Trust are leveraging DERM autonomously to do this in today's webinar. If you can't attend, register to receive the recording: https://lnkd.in/eB9CHEKm https://lnkd.in/eZsCyBeY

🛡️4 years of James Hamlyn, Skin Analytics Quality Assurance and Regulatory Affairs Director. James leads in ensuring Skin Analytics technologies are compliant with medical device regulations and meet quality standards, as well as maintaining quality systems and programs. James fosters a culture of quality excellence and accountability, driving our company-wide commitment to delivering effective quality management systems that are evaluated against the best in class standards. Thanks to James, Skin Analytics recently reached an incredible regulatory milestone and a fundamental turning point for the future of dermatology - securing DERM a Class III CE mark under the European Medical Device Regulation (MDR). One small step for James, one giant leap for dermatology 😉 https://lnkd.in/e9G4Hpq4

⏰ 2 days to go! Register your space now 👇 💡 🧠 Autonomous AI in action: Tackling NHS backlogs and improving patient outcomes in dermatology 🧠 💡 Webinar | February 12th | 12pm - 1pm Hear from Chelsea and Westminster Hospital NHS Foundation Trust and how they're leveraging DERM autonomously to: - Release up to 30% of appointments with consultants for patients with skin cancer and inflammatory skin conditions like eczema and psoriasis - Safely discharge and reassure patients with benign lesions more quickly - Free up dermatologists who are now able to process an additional 25% of teledermatology patients. Register here: https://lnkd.in/eB9CHEKm Chelsea and Westminster Hospital NHS Foundation Trust CW+ charity NHS Providers Lucy Thomas Keith Grimes Audrey Menezes

👏🚨DERM makes medical history as world’s first autonomous skin cancer detection system approved for clinical decisions in Europe🚨👏 DERM has received its Class III CE mark, a regulatory milestone marking the highest level of conformity assessment in Europe under the Medical Device Regulation (MDR) 2017/745. This achievement represents the first time an AI as a Medical Device (AIaMD) has attained the highest regulatory clearance within the cancer field and is able to operate autonomously in Europe. The EU MDR Class III evaluation is the most rigorous assessment of a medical technology in Europe, typically reserved for critical devices like pacemakers or neurological implants. More here: https://lnkd.in/e9G4Hpq4

"We have been hearing about AI in healthcare for many years now but this is a real watershed moment in the history of medicine.” DERM from Skin Analytics has been awarded EU’s first and only Class III CE marked medical device, making it the world’s first legally authorised autonomous AI for detecting cancer according to the company. Read more: https://lnkd.in/eUkvMppJ #MedTech #AI #Diagnostics #SkinCancer

The NHS 2025/26 priorities and operational planning guidance - how we can help. Our real-world NHS deployments show: ✅ AI is the only truly scalable solution that can reduce the time people wait for elective care in dermatology. We see a 20-40% USC pathway discharge rate in secondary care and 55-65% of USC referrals avoided in primary care. Reserving or redirecting that capacity can make a huge difference. ✅ Improving productivity in cancer pathways including teledermatology. But teledermatology alone is not enough. It still relies on the same overstretched workforce to see 100% of patients. Using AI with teledermatology is the only way to free up specialist-level capacity and meet demand. We are already using AI autonomously in the NHS to discharge up to 40% of patients before teledermatology review. ✅ Maximising care for low-risk patients in non-cancer settings. Our NHS partners use additional capacity gains from the implementation of DERM to see and treat patients with inflammatory skin diseases who previously endured long wait times on routine pathways where conditions and quality of life worsen. See how we're helping: https://lnkd.in/eHdDmsW8

This week, some of the Skin Analytics clinical team attended The Royal College of Radiologists Global AI Conference. 💡Dr Dilraj K. presented DERM’s real-world performance across our NHS deployments, demonstrating the transformative impact regulated AI can have at scale for system sustainability and driving better patient outcomes. 💡Dr Karan Punjabi presented our statistically led audit methodology for post-market surveillance of DERM. Following an independent evaluation commissioned by NHS England, our process emphasises tracking negative predictive value to maintain AI accuracy, describing minimum sample sizes required and audit frequency. More on DERM’s performance and the Skin Anaytics post-market surveillance process here: https://lnkd.in/edwh_DBd